FDA Accepts Molecular Templates IND for MT-8421 ETB Program Targeting CTLA-4

(24/7 MARKET NEWS) – Molecular Templates, Inc. (NASDAQ: MTEM) announced, during yesterday’s market hours, that it received FDA clearance following review of its Investigational New Drug Application (“IND”) to proceed for clinical testing of its novel MT-8421 ETB program targeting CTLA-4 in patients with relapsed/refractory solid tumors previously exposed to checkpoint inhibitors.

Molecular Templates is trading at $0.60 up $0.13 (+27.23%), on 6.8 million premarket shares.

Its 52-week trading range is $0.31 to $3.6365. It’s trading at new 2023 highs and above yesterday’s $0.55 high, on much higher volume, so this is a move to keep an eye on, as there are only low volume resistance points to July’s $1 trading level.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist